MRK - What's Behind NovoCure's Recent Gains And What's Ahead
- Shares of NovoCure have doubled since July '20.
- The recent gains seem to have been inspired by the company teaming up with pharmaceutical giant, Merck, in first-line NSCLC, and growing acceptance in the medical community.
- Furthermore, many catalysts are on the horizon in 2021 and years beyond, potentially opening up the floodgates of revenue across several different oncologic indications.
- Challenges ahead include questions of data veracity, device compliance, and access to capital.
- NovoCure remains a conviction pick, as it pushes TTFields towards critical relevance in the treatment of solid tumors.
For further details see:
What's Behind NovoCure's Recent Gains And What's Ahead